This biotech is buzzing! 🐝 News of human trials and Nasdaq compliance lit a fire, with the chart showing a clear breakout from the $2.60s to kiss $3.00. The volume surge confirms this isn't a fluke. The move feels a bit extended short-term, but the momentum is undeniable. This is a BUY on any dip. #RocketFuel

"Portage Biotech is buzzing like a beehive after a sugar rush! 🐝 Human trial prep and solid preclinical results have the stock popping, but the technicals tell a cautious tale—WMAs are still sloping down, and RSI is stuck in 'meh' territory (46.45). Volume spiked on news days but fizzled fast. Chart’s messy—no clean pattern, just post-news whiplash. News is hot, but the stock’s still digesting. Hold for now, but keep a finger on the trigger if it breaks $8.05. #BiotechRollercoaster"

Portage Biotech’s stock is on a wild ride! 🚀 The price surged from $5.14 to $8.59 on April 11, with massive volume (31M shares)—classic FOMO momentum. The 9-day EMA just crossed above the 21-day EMA, a bullish signal. RSI hit 70, nearing overbought territory, so caution ahead. News of positive trial results and financing fueled the rally. Short-term? Hold if you’re in, but watch for a pullback—RSI suggests overheating. Long-term? Depends on trial outcomes. High risk, high reward! 💥

Portage Biotech's stock saw a significant surge in value yesterday following a series of positive news announcements regarding its clinical trials and financial activities. The stock price showed bullish momentum throughout the day, reaching a high of $10.68 before settling at $9.65, with impressive trading volume indicating strong investor interest. The Relative Strength Index (RSI) is currently neutral, suggesting a potential for further upside movement. Key resistance levels to watch for are around $10.00, while support can be found near $9.40 based on recent price action. The news sentiment surrounding Portage Biotech seems optimistic, with the company making strides in its research and funding activities, which could continue to drive positive price action in the near term. Overall, the stock appears to be in a bullish trend fueled by favorable news catalysts.